Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

SYDNEY, April 1, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-E-002-1) in ovarian cancer. The poster will be presented at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA at 1:00pm EST on Monday 1 April 2019. The poster number is CT019 and is available for download from the Company's website.

Dr James Garner, Chief Executive Officer of Kazia Therapeutics commented, "we are delighted to be able to share positive results from the first part of the Cantrixil phase I study in ovarian cancer, and it is very encouraging to have been selected to do so at a conference as prestigious as AACR."

Key Points

• Part A of the study was performed at five sites in the United States and Australia. Fourteen patients were enrolled in total, of which eleven received at least one dose of Cantrixil
• A Maximum Tolerated Dose (MTD) of 5mg/kg was determined. This is well within the predicted therapeutic range, based on preclinical data, and supports moving forward with subsequent clinical development
• Of nine patients evaluable for efficacy, five (56%) achieved stable disease after two cycles of Cantrixil monotherapy. One of these five patients subsequently achieved a partial response when Cantrixil was administered with chemotherapy, as intended per protocol
• Main side effects were gastrointestinal in nature, with abdominal pain and fatigue being the most common drug-related observations, although not generally dose-limiting
• An expansion cohort is currently underway to seek efficacy signals, and is planned to enroll 12 patients, all of whom will receive a dose of 5 mg/kg; initial data from this cohort is expected in 2H of calendar 2019

Dr Garner continued, "phase I studies are always primarily safety studies. The data from this study shows that Cantrixil has a safety profile very suitable for further development, and we have been able to reach a dose well within the predicted therapeutic range. It is extremely positive that we have seen some preliminary evidence of efficacy at this early stage in development, and the ongoing Part B of the study should give us much more information."

The AACR Annual Meeting is one of the largest and most prestigious cancer research meetings in the world. Clinical trial abstracts are selected for presentation if they contain impactful new data with the potential to influence treatment practice. The conference brings together more than 20,000 representatives from academia, industry, government and advocacy organisations from across the globe.

The phase I study of Cantrixil commenced in December 2016 and is registered on clinicaltrials.gov as NCT02903771. It is structured in two parts: Part A aimed to understand the safety profile of Cantrixil and to establish the Maximum Tolerated Dose (MTD), while Part B will recruit 12 patients at the MTD to seek preliminary signals of efficacy. Recruitment to Part B remains ongoing, and Kazia expects to report initial data from this component of the study in the second half of calendar 2019.

Following the recent opening of an additional site, the study is currently being conducted at six hospitals in the United States and Australia:

Daniel Berg, Clinical Program Director for Cantrixil, commented, "we are fortunate to be working with some of the leading specialists in this disease area. Ovarian cancer remains a disease with significant unmet clinical need, and we believe Cantrixil may represent an important addition to therapeutic protocols."

The study protocol was designed such that patients received two cycles (six weeks) of therapy with Cantrixil alone, followed by up to six cycles (eighteen weeks) of Cantrixil administered in combination with standard-of-care chemotherapy. In total, 14 patients were enrolled in Part A. However, three patients were withdrawn before receiving a first dose of Cantrixil due to rapid disease progression or other aspects of their pre-existing condition, leaving 11 patients evaluable for safety. Of these, nine patients completed the first cycle of treatment with Cantrixil, making them evaluable for determination of the MTD.

The study enrolled patients at doses ranging from 0.24 mg/kg to 20 mg/kg, and 5 mg/kg was determined to be the maximum tolerated dose. This is within the therapeutic range that would be predicted from preclinical data. The main adverse events were gastrointestinal in nature, and included abdominal pain, ileus, and bowel obstruction. Diarrhoea, nausea, and vomiting were also seen, but were not generally dose-limiting.

All patients had recurrent or persistent ovarian cancer and had failed at least two prior lines of therapy, including platinum therapy, prior to study entry, representing a very advanced population. After two cycles of treatment with Cantrixil, five of nine evaluable patients (56%) achieved stable disease, according to the industry-standard RECIST criteria, which means that the tumour remained approximately the same size over time and had not progressed. One of these patients subsequently achieved a partial response when Cantrixil was administered with standard-of-care chemotherapy, which means that the tumour was reduced in size by 30% or more.

Four out of nine patients (44%) remained on study drug for the entire 24-week duration of the study (approximately six months), without experiencing progression of their disease. For comparison, data from other studies in a similar patient group has found a progression-free survival of approximately 3.4 to 4.7 months. This further suggests the possibility that Cantrixil may help to delay disease progression.

Ovarian cancer is diagnosed in approximately 240,000 women each year worldwide and is the eighth most common cause of cancer death in women. Conventional treatment typically includes surgery, radiotherapy, and chemotherapy. However, the five-year survival rate remains low, at approximately 45%, reflecting the fact that the disease is often advanced at the time of diagnosis.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Logo - https://mma.prnewswire.com/media/766762/Kazia_Logo.jpg

SOURCE Kazia Therapeutics Limited